The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

Chugai announces Roche to discontinue development of emugrobart in spinal muscular atrophy and FSHD: Tokyo Tuesday, March 24, 2026, 14:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd.

Your muscles need continuous maintenance to stay strong and healthy. Duchenne muscular dystrophy (DMD) happens when there is a change in a person's genetic instructions that affects the production of ...

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater ...

Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle ...

Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including charting and trades.

The muscular dystrophies are commonly associated with cardiovascular complications, including cardiomyopathy and cardiac arrhythmias. These complications are caused by intrinsic defects in ...

Eight therapies are approved for Duchenne muscular dystrophy (DMD) in the U.S., and all have been approved since 2016. "It took 30 years from the discovery of the gene associated with Duchenne ...

We hypothesize that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur with a greater than random frequency. In this study, we set out to reject the ...

Mesquite firefighters will be trading their gear for boots — donation boots, that is — as the Mesquite Firefighters ...